Phosphodiesterase 4 inhibitors reduce human dendritic cell inflammatory cytokine production and Th1-polarizing capacity.
TLDR
Findings indicate that PDE4 inhibitors can affect T cell responses by acting at the DC level and may increase the understanding of the therapeutic implication of PDE 4 inhibitors for T(h)1-mediated disorders.Abstract:
Inhibitors of cAMP-specific phosphodiesterase (PDE) 4 have been shown to inhibit inflammatory mediator release and T cell proliferation, and are considered candidate therapies for T(h)1-mediated diseases. However, little is known about how PDE4 inhibitors influence dendritic cells (DC), the cells responsible for the priming of naive T(h) cells. Therefore, we investigated the PDE profile of monocyte-derived DC, and whether PDE4 inhibitors modulate DC cytokine production and T cell-polarizing capacity. We mainly found cAMP-specific PDE4 enzymatic activity in both immature and mature DC. In contrast to monocytes that mainly express PDE4B, we found that PDE4A is the predominant PDE4 subtype present in DC. Immature DC showed reduced ability to produce IL-12p70 and tumor necrosis factor (TNF)-alpha upon lipopolysaccharide or CD40 ligand (CD40L) stimulation in the presence of PDE4 inhibitors, whereas cytokine production upon CD40L stimulation of fully mature DC in the presence of PDE4 inhibitors was not affected. Exposure to PDE4 inhibitors for 2 days during DC maturation did not influence T cell-stimulatory capacity or acquisition of a mature phenotype, but increased the expression of the chemokine receptor CXCR4. Furthermore, DC matured in the presence of PDE4 inhibitors showed reduced capacity to produce IL-12p70 and TNF-alpha upon subsequent CD40L stimulation. Using these PDE4 inhibitor-matured DC to stimulate naive T cells resulted in a reduction of IFN-gamma-producing (T(h)1) cells. These findings indicate that PDE4 inhibitors can affect T cell responses by acting at the DC level and may increase our understanding of the therapeutic implication of PDE4 inhibitors for T(h)1-mediated disorders.read more
Citations
More filters
Journal ArticleDOI
Identifying druglike inhibitors of myelin-reactive T cells by phenotypic high-throughput screening of a small-molecule library.
TL;DR: 6 nontoxic compounds with a molecular weight <500 that inhibited inflammatory responses in PLP-reactive T cells in a concentration-dependent fashion are identified and represent valid leads that may be developed into novel therapeutics for MS that could be administered orally.
Journal ArticleDOI
Cilomilast, an orally active phosphodiesterase 4 inhibitor for the treatment of COPD
TL;DR: Cilomilast has been shown to be well tolerated in both short- and long-term studies in doses of up to 15 mg twice daily and is thus a promising substance for use in the anti-inflammatory treatment of COPD.
Book ChapterDOI
Phosphodiesterase (PDE) Inhibitors for the Treatment of Inflammatory Skin Conditions
TL;DR: An overview of the role of PDE inhibition in the treatment of inflammatory skin disease is provided and ongoing developments for this novel drug class are discussed.
Journal ArticleDOI
Review of potential medical treatments for middle ear cholesteatoma
TL;DR: In this article , a review was targeted at connecting the dysregulated inflammatory network of MEC to pathogenesis and identification of pharmaceutical targets, which can be used as attack points for pharmaceuticals.
Journal ArticleDOI
Interaction between saliva's adenosine and tick parasitism: effects on feeding and reproduction.
Elen Anatriello,Carlo José Freire Oliveira,Nathália Teresinha Baptista Oliveira,Andressa Fisch,Cristiane M. Milanezi,João Santana da Silva,Isabel Kinney Ferreira de Miranda-Santos,Beatriz Rossetti Ferreira +7 more
TL;DR: It is suggested that ADO produced by ticks helps them feed and reproduce and that this effect may be due to modulation of host DCs and T cells.
References
More filters
Journal ArticleDOI
Dendritic cells and the control of immunity
TL;DR: Once a neglected cell type, dendritic cells can now be readily obtained in sufficient quantities to allow molecular and cell biological analysis and the realization that these cells are a powerful tool for manipulating the immune system is realized.
Journal ArticleDOI
Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha.
TL;DR: Cultured DCs are as efficient as antigen-specific B cells in presenting tetanus toxoid (TT) to specific T cell clones and their efficiency of antigen presentation can be further enhanced by specific antibodies via FcR- mediated antigen uptake.
Journal ArticleDOI
Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products.
TL;DR: The capacity of DCs to capture and process antigen could be modulated by exogenous stimuli was investigated and it was found that DCs respond to tumor necrosis factor alpha, CD40 ligand, IL-1, and lipopolysaccharide with a coordinate series of changes that include downregulation of macropinocytosis and Fc receptors, disappearance of the class II compartment, and upregulation of adhesion and costimulatory molecules.
Journal ArticleDOI
Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation.
TL;DR: It is found that ligation of CD40 by CD40L triggers the production of extremely high levels of bioactive IL-12, which is the most potent stimulus in upregulating the expression of ICAM-1, CD80, and CD86 molecules on DCs.
Journal ArticleDOI
Chemokines and chemokine receptors in T-cell priming and Th1/Th2-mediated responses
TL;DR: The role played by chemokines and chemokine receptors in positioning T cells for the immune response is reviewed, with a focus on T-cell priming and delayed-type hypersensitivity or allergic reactions.